Literature DB >> 31731269

Imaging characteristics of adult H3 K27M-mutant gliomas.

Tianming Qiu1, Apisara Chanchotisatien2, Zhiyong Qin1, Jinsong Wu1, Zunguo Du3, Xialing Zhang3, Fangyuan Gong1, Zhenwei Yao4, Shuguang Chu5.   

Abstract

OBJECTIVE: H3 K27M-mutant gliomas present heterogeneously in terms of pathology, imaging, and prognosis. This study aimed to summarize the imaging characteristics of adult H3 K27M-mutant gliomas.
METHODS: The authors retrospectively identified all cases of glioma diagnosed using histopathological studies (n = 3300) that tested positive for histone H3 K27M mutations (n = 75) between January 2016 and December 2018 in a single hospital. Preoperative and follow-up MR images of 66 adult patients (age ≥ 18 years) were reviewed for anatomical location, degree of contrast enhancement, enhancement patterns, hemorrhage, edema, diffusion restriction, tumor dissemination, and tumor spread.
RESULTS: The study included 66 cases (40 in men, 26 in women) of H3 K27M-mutant glioma in adult patients. Tumors were found in the following sites: thalamus (n = 38), brainstem (n = 6), brainstem with cerebellar or thalamic involvement (n = 4), whole brain (n = 8), corpus callosum (n = 3), hypothalamus (n = 1), hemispheres (n = 2), and spinal cord (n = 4). All pure brainstem lesions were located posteriorly, and all corpus callosal lesions were in the genu. Most spinal tumors were long-segment lesions. Hemispheric lesions mimicked gliomatosis cerebri in presentation, with the addition of traditional midline structure involvement. Most tumors were solid with relatively uniform signals on plain MRI. Of the 61 cases with contrast-enhanced MR images, 36 (59%) showed partial to no enhancement, whereas 25 (41%) showed diffuse or irregular peripheral enhancement. Hemorrhage and edema were rare. Most lesions were solid and showed mild diffusion restriction on diffusion-weighted imaging. Tumor dissemination to the leptomeninges (n = 8) and subependymal layer (n = 3) was observed.
CONCLUSIONS: The authors described the MRI features of diffuse midline glioma with H3 K27M mutation in the largest study done to date in adult patients. Tumors were found in both midline and nonmidline structures, with the thalamus being the most common site. Although adult H3 K27M-mutant gliomas demonstrated highly variable presentations in this cohort of patients, the authors were able to observe shared characteristics within each location.

Entities:  

Keywords:  DWI = diffusion-weighted imaging; H3 K27M = histone H3 lysine27-to-methionine mutation; H3 K27M-mutant; MR imaging; glioma; oncology

Year:  2019        PMID: 31731269     DOI: 10.3171/2019.9.JNS191920

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  12 in total

1.  Non-invasive diagnosis of H3 K27M mutant midline glioma.

Authors:  Raymond Y Huang; Jeffrey P Guenette
Journal:  Neuro Oncol       Date:  2020-03-05       Impact factor: 12.300

2.  A curious case of T2-FLAIR mismatch in H3K27M mutant glioma.

Authors:  William L Valentino; Darren Okada; Shiv Bhanu
Journal:  Radiol Case Rep       Date:  2022-06-17

3.  Imaging characteristics of H3 K27M histone-mutant diffuse midline glioma in teenagers and adults.

Authors:  Stefanie Thust; Caroline Micallef; Sachi Okuchi; Sebastian Brandner; Atul Kumar; Kshitij Mankad; Stephen Wastling; Laura Mancini; Hans Rolf Jäger; Ananth Shankar
Journal:  Quant Imaging Med Surg       Date:  2021-01

4.  Exploring MRI Characteristics of Brain Diffuse Midline Gliomas With the H3 K27M Mutation Using Radiomics.

Authors:  Qian Li; Fei Dong; Biao Jiang; Minming Zhang
Journal:  Front Oncol       Date:  2021-05-24       Impact factor: 6.244

Review 5.  Advancements in Neuroimaging to Unravel Biological and Molecular Features of Brain Tumors.

Authors:  Francesco Sanvito; Antonella Castellano; Andrea Falini
Journal:  Cancers (Basel)       Date:  2021-01-23       Impact factor: 6.639

6.  Clinical Features and Molecular Markers on Diffuse Midline Gliomas With H3K27M Mutations: A 43 Cases Retrospective Cohort Study.

Authors:  Yuan Wang; Lan-Lan Feng; Pei-Gang Ji; Jing-Hui Liu; Shao-Chun Guo; Yu-Long Zhai; Eric W Sankey; Yue Wang; Yan-Rong Xue; Na Wang; Miao Lou; Meng Xu; Min Chao; Guo-Dong Gao; Yan Qu; Li Gong; Liang Wang
Journal:  Front Oncol       Date:  2021-02-15       Impact factor: 6.244

7.  Spinal Cord Diffuse Midline Glioma, H3K27M- mutant Effectively Treated with Bevacizumab: A Report of Two Cases.

Authors:  Satoru Yabuno; Satoshi Kawauchi; Michiari Umakoshi; Atsuhito Uneda; Kentaro Fujii; Joji Ishida; Yoshihiro Otani; Yasuhiko Hattori; Nobushige Tsuboi; Shohei Kohno; Mai Noujima; Tomohiro Toji; Hiroyuki Yanai; Takao Yasuhara; Isao Date
Journal:  NMC Case Rep J       Date:  2021-08-21

8.  Multiparametric MRI-Based Radiomics Model for Predicting H3 K27M Mutant Status in Diffuse Midline Glioma: A Comparative Study Across Different Sequences and Machine Learning Techniques.

Authors:  Wei Guo; Dejun She; Zhen Xing; Xiang Lin; Feng Wang; Yang Song; Dairong Cao
Journal:  Front Oncol       Date:  2022-03-03       Impact factor: 6.244

9.  Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults.

Authors:  Jessica D Schulte; Robin A Buerki; Sarah Lapointe; Annette M Molinaro; Yalan Zhang; Javier E Villanueva-Meyer; Arie Perry; Joanna J Phillips; Tarik Tihan; Andrew W Bollen; Melike Pekmezci; Nicholas Butowski; Nancy Ann Oberheim Bush; Jennie W Taylor; Susan M Chang; Philip Theodosopoulos; Manish K Aghi; Shawn L Hervey-Jumper; Mitchel S Berger; David A Solomon; Jennifer L Clarke
Journal:  Neurooncol Adv       Date:  2020-10-22

10.  Differences in the MRI Signature and ADC Values of Diffuse Midline Gliomas with H3 K27M Mutation Compared to Midline Glioblastomas.

Authors:  Peter Raab; Rouzbeh Banan; Arash Akbarian; Majid Esmaeilzadeh; Madjid Samii; Amir Samii; Helmut Bertalanffy; Ulrich Lehmann; Joachim K Krauss; Heinrich Lanfermann; Christian Hartmann; Roland Brüning
Journal:  Cancers (Basel)       Date:  2022-03-09       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.